SEC Compliant

sto public sale

Participate in one of the world’s first examples of a tokenized preferred equity investment, backed by a revenue royalty stream.
Investor Registration

act now:

round 1 public sale is open for a limited amount of time

RDG Security Token Considerations

  • Per Security Token Round 1 face value of $1.00.
  • Total fixed security token supply of 100 million with a very limited amount of 20 million being sold during Round 1.
  • Each security token represents a TOKENIZED DIGITAL SECURITY with a direct royalty claim against a portion of Radiologex platform revenues, and proceeds from potential monetization of the business (e.g. sale or IPO), with dividends PAID quarterly and automatically dropped into your dashboard or wallet.
  • Prospective access to secondary market not typically available with traditional startup investments.
  • Upcoming exchange listings.* Opening the ability to trade RDG tokens on secondary markets
  • Minimum investment of $5000 for US/$2500 for non-US (Worldwide). Limited Investor Pool.
  • USD AND EURO accepted now via Wire/ACH/Check. Crypto investments now available on Securitize dashboard, accepting BTC/ETH/USDT/USDC.
  • Sold by Radiologex, a USA-based company.
Download Pitch Deck


Have Questions?
Click here to chat LIVE with a member of the executive team.

Email Us
Support is available 24/7 at invest@radiologex.com

Token Audit Certificate
Token Audit (ERC20 Contract)



Register to Invest Now!
Trust is never assumed, it is built in™.
* Per compliance time-out requirements for dates of live listings.
*2020 Macbook Air 13-inch, M1 Chip with 8-Core CPU and 7-Core GPU, 256GB storage, based on avalability.

Get a free Apple MacBook Air*

(limited up to first 500 investors)

Tier 1 = $50,000.00 and up (USD or Crypto) (2x)
100% RDG Bonus
plus 2021 MacBook

Tier 2 = $25,000.00 - $49,999.99 (USD or Crypto) (1.75x)
75% RDG Bonus
plus 2021 MacBook

Tier 3 = $15,000.00 - $24,999.99 (USD or Crypto) (1.50x)
50% RDG Bonus

Tier 4 = $2,500.00 (USD or Crypto) (1.25x)
25% RDG Bonus

Limited Time Referral Bonus up to 100%*
(first 100 referrals only)

Register to Invest Now!
*Referral bonus details available at invest@radiologex.com, contact us for your referral code.
The following countries are currently not accepted through Securitize. Users in these countries can contact us directly using the chat button on this page and we can notify them when we are added to secondary exchanges that allow these regions. Currently blocked: Afghanistan, Belarus, Congo, Cote D'Ivoire, Cuba, Iraq, Iran, North Korea, Liberia, Myanmar, Sudan, South Sudan, Syrian Arab Republic, Ukraine, Zimbabwe
R-DEE Product and STO

The offering by Radiologex:


SEC-compliant REG D (Reg S) filing investment offering.

Commercial-ready (already BUILT) product.

Turnkey and easy-to-use investment onboarding and tracking dashboard built by Securitize, an SEC-registered transfer agent, featuring push-button dividend distributions (auto airdrop of quarterly dividends), an innovative and elevated investor user experience for earnings, and data tracking (including historical and tax data on earnings, etc).

Unique and transparent security token investment offering (tokenized asset-backed security with a FIXED maximum limit) that represents a direct royalty claim against a portion of revenue generated on the Radiologex platform (not a cryptocurrency or utility token investment).


The backing product and platform by Radiologex:


USA-based healthcare technology company, Radiologex and its global network called “R-DEE” (HealthIT).

Robust software platform providing ultra-fast and cutting-edge data delivery with patented user authentication and verification technology, creating the largest and safest Global Healthcare participant community and ecosystem.

R-DEE is a collaboration and productivity suite built upon a vast distributed content delivery and data storage network. Built from the ground up for next-gen, borderless, medical and healthcare interactivity for the $9 Trillion Global Healthcare industry.*

Successful product release and rollout as of May 1, 2021 (limited), with over 400 organizations on the R-DEE waitlist awaiting General Product Release (LIVE) in 2022. Currently over 10 institutions and groups are in BETA testing and live UATs.

The only ZERO-TRUST built technological architecture available in Health IT designed to eliminate redundancy and dangerously unsecured legacy systems.

Secure IP + Certified Technology features including: ISO 9001 and ISO 27001, US GOV ONC-US Dept. Human and Health Services certified, as well as full utility patent-pending (USA filed and PTO). FHIR/EHR ready. Vendor neutral ready. Network can deliver 3rd party software and apps. Accessibility of platform via ANY device or web (both app and platform built).

Strong business model with multiple revenue streams derived from eight different business modules/services, including SaaS (subscription model), transaction fees, commission fees, settlement fees, and advertising revenue.

DISCLAIMER: Purchase of RDG Tokens is NOT considered accepted until Radiologex notifies the investor that its subscription agreement has been accepted (but in no event less than 75 days), and can be refused for any reason or no reason including but not limited to: any regulatory reasons, deficiency in KYC, or other investor screening reasons, all being in the sole and absolute discretion of Radiologex. The funds are accepted in units of United States of America (USA) dollars and refunded in units of USA dollars, irrespective of the medium in which they are paid. In the case they are sent or received in accepted forms of crypto currency or other country's fiat currency, the conversion will be at any commercially-reasonable exchange rate at the moment of receipt or refund.

ALL Securities sold subject to max of 50M tokens sold or $20m raised whichever comes first.

This communication does not constitute an offer or a solicitation to purchase securities, as that term is defined in the United States under the Securities Act of 1933 (“the Act”), or in any other jurisdiction. A definitive offer to purchase or sell securities can only be made through long-form offering documents including a Subscription Agreement. Any decision to purchase security tokens in connection with a prospective offering should be made solely on the basis of the information contained in any then-current Offering Circular, Subscription Agreement, and ancillary documents, which should be carefully-reviewed and evaluated in consultation with the prospective purchaser's legal, accounting, investment, tax and any other applicable advisors, in view of the prospective purchaser's circumstances. For avoidance of doubt, this communication does not constitute a purchase recommendation regarding any security tokens proposed or intended to be offered or sold by Radiologex Technologies, LLC.

Note Regarding Forward-Looking Statements Radiologex cautions that statements in this communication that are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties that may impact actual results of operations and prospective transactions. These forward-looking statements include, among other things, statements about the health information technology and blockchain markets and the offer and consummation of contemplated transactions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Such statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, without limitation: the risk of divergent business climate, health care sector and/or health information technology developments; the risk that anticipated transaction(s) may fail to obtain due to factors outside of our control; the outcome of any legal proceedings, regulatory proceedings or enforcement matters; adverse changes in the funding markets (including the markets for blockchain security tokens); and changes in the terms, scope or timing of contracts, contract cancellations, and other modifications and actions by customers and other business counterparties of LK Group, Inc. or Radiologex, LLC. If one or more of these or unknown risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of Radiologex’s management as of the date hereof. Except to the extent required by applicable law, Radiologex undertakes no obligation to update or revise any forward-looking statement.
Radiologex.
500 Delaware Ave, Ste 1 #1960, Wilmington, DE 19899